scholarly journals NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021

2021 ◽  
Vol 19 (8) ◽  
pp. 888-895
Author(s):  
Nadeem R. Abu-Rustum ◽  
Catheryn M. Yashar ◽  
Kristin Bradley ◽  
Susana M. Campos ◽  
Junzo Chino ◽  
...  
Keyword(s):  
Treatment Options ◽  
Molecular Profiling ◽  
Uterine Sarcoma ◽  
Clinical Staging ◽  
Uterine Neoplasms ◽  
Uterine Sarcomas ◽  
Nccn Guidelines ◽  
Recent Addition ◽  
Diagnosis Classification ◽  
Classification And Treatment

The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer or uterine sarcoma. These NCCN Guidelines Insights focus on the recent addition of molecular profiling information to aid in accurate diagnosis, classification, and treatment of uterine sarcomas.

Intraventricular hemorrhage and posthemorrhagic hydrocephalus in preterm infants: diagnosis, classification, and treatment options

2019 ◽  
Vol 35 (6) ◽  
pp. 917-927 ◽  
Author(s):  
Paola Valdez Sandoval ◽  
Paola Hernández Rosales ◽  
Deyanira Gabriela Quiñones Hernández ◽  
Eva Alejandra Chavana Naranjo ◽  
Victor García Navarro
Keyword(s):  
Preterm Infants ◽  
Intraventricular Hemorrhage ◽  
Treatment Options ◽  
Posthemorrhagic Hydrocephalus ◽  
Diagnosis Classification ◽  
Classification And Treatment

scholarly journals Invasive Cervical Resorption: Etiology, Diagnosis, Classification and Treatment

2012 ◽  
Vol 13 (5) ◽  
pp. 723-728 ◽  
Author(s):  
José Augusto César Discacciati ◽  
Eduardo Lemos de Souza ◽  
Sérgio Carvalho Costa ◽  
Herbert Haueisen Sander ◽  
Vinícius de Magalhães Barros ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
Treatment Options ◽  
Interdisciplinary Treatment ◽  
Osseointegrated Implants ◽  
Inappropriate Treatment ◽  
First Choice ◽  
Choice Of Treatment ◽  
External Trauma ◽  
Diagnosis Classification ◽  
Classification And Treatment

ABSTRACT Background Invasive cervical resorption (ICR) is not well understood by the professional, being misdiagnosed, leading to inappropriate treatment and unnecessary loss of tooth. Introduction ICR is defined as a localized process of resorption, which begins in the cervical area of the tooth, just below the epithelial junction and above the ridge crest in the area of the connective tissue insertion. Possible predisposing factors include external trauma, orthodontic movement, surgical procedures, periodontal disease and its treatments, endogenous bleaching, pressure generated by wind instruments and herpes virus infection. Different approaches have been suggested for the treatment of ICR, depending on the extent of the lesion and its location. However, in some cases due to the severity of the injury, there is no alternative but to tooth extraction, followed by restoration of the edentulous area. Aim and objective Discuss etiology, diagnosis and classification of the ICR, as well as different treatment options. Also is presented a case in which extraction was carried out, installation of the implant and ceramic crown, subsequent to a treatment approach that resulted in failure in the short-term period. Conclusion Early diagnosis of the ICR is critical to proper treatment and favorable prognosis. Interdisciplinary treatment should be instituted as soon as possible, avoiding the loss of the affected tooth. In advanced cases, treatment involving the installation of osseointegrated implants should be considered the first choice of treatment. Clinical significance Early diagnosis of the ICR is critical do prevent unnecessary tooth loss, once the prognosis for advanced cases is doubtful. How to cite this article Discacciati JAC, de Souza EL, Costa SC, Sander HH, Barros VM, Vasconcellos WA. Invasive Cervical Resorption: Etiology, Diagnosis, Classification and Treatment. J Contemp Dent Pract 2012;13(5):723-728.

scholarly journals The Management of Older Adults with Pancreatic Adenocarcinoma

Geriatrics ◽  
2018 ◽  
Vol 3 (4) ◽  
pp. 85 ◽  
Author(s):  
John Ogden ◽  
Hao Xie ◽  
Wen Ma ◽  
Joleen Hubbard
Keyword(s):  
Older Adults ◽  
Pancreatic Cancer ◽  
Clinical Trial ◽  
Treatment Options ◽  
Karnofsky Performance Score ◽  
Nccn Guidelines ◽  
The Us ◽  
Localized Disease ◽  
Clinical Trial Enrollment ◽  
Current Guidelines

Pancreatic cancer is the eleventh most common cancer, yet it is the third leading cause of mortality. It is also largely a disease of older adults, with the median age of 71 at diagnosis in the US, with <1% of diagnoses occurring prior to age 50. Current NCCN guidelines recommend surgery for localized disease, followed by adjuvant therapy and/or consideration of enrollment in a clinical trial. For metastatic disease, current guidelines recommend clinical trial enrollment or systemic chemotherapy based on results from the landmark ACCORD-11 and MPACT trials. However, these trials focused heavily on younger, more fit patients, with the ACCORD-11 trial excluding patients over age 75 and the MPACT trial having 92% of its patients with a Karnofsky performance score >80. This article summarizes the available evidence in current literature in regards to the best treatment options for older adults, who represent the majority of pancreatic cancer diagnoses.

Uterine Leiomyoma or Sarcoma?

2021 ◽  
pp. 289-304
Author(s):  
Theodoros Theodoridis ◽  
Dimitra Aivazi ◽  
Leonidas Zepiridis ◽  
Nikolaos Vlachos
Keyword(s):  
Differential Diagnosis ◽  
Smooth Muscle ◽  
Connective Tissue ◽  
Muscle Cells ◽  
Uterine Sarcoma ◽  
Current Evidence ◽  
Optimal Management ◽  
Benign Neoplasms ◽  
Uterine Sarcomas ◽  
Epithelial Neoplasms

Uterine leiomyomas are benign neoplasms derived from the smooth muscle cells of the myometrium. In contrast, uterine sarcomas are rare tumors, with a prevalence of 3-7 per 100,000 women, originating from myometrial cells or endometrial connective tissue. Uterine sarcomas and especially leiomyosarcomas are more aggressive than uterine epithelial neoplasms. The differential diagnosis between leiomyoma and uterine sarcoma preoperatively remains challenging for the clinical practitioner in order to determine optimal treatment. The chapter aims to summarize current evidence regarding differential diagnosis and optimal management of these two challenging clinical entities.

Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature

2009 ◽  
Vol 19 (2) ◽  
pp. 245-248 ◽  
Author(s):  
Frédéric Amant ◽  
An Coosemans ◽  
Vincent Renard ◽  
Els Everaert ◽  
Ignace Vergote
Keyword(s):  
Clinical Benefit ◽  
Response Rate ◽  
Uterine Sarcoma ◽  
Current Data ◽  
Clinical Impact ◽  
High Grade ◽  
Review Of The Literature ◽  
Uterine Sarcomas ◽  
Previously Treated ◽  
Undifferentiated Uterine Sarcoma

AbstractThe clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which 1 had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of 11 patients with a clinical benefit in 7 (64%) of 11 patients. These results on the use of ET-743 in uterine sarcoma patients support the conductance of larger trials.

Non-puerperal uterine inversion in association with uterine sarcoma: clinical management

2003 ◽  
Vol 13 (2) ◽  
pp. 244-245 ◽  
Author(s):  
M. Moodley ◽  
J. Moodley
Keyword(s):  
Surgical Procedures ◽  
Clinical Management ◽  
Vaginal Discharge ◽  
Uterine Sarcoma ◽  
Rare Entity ◽  
Vaginal Route ◽  
Uterine Sarcomas ◽  
Vaginal Mass ◽  
Uterine Inversion ◽  
Abdominal Route

Non-puerperal uterine inversion due to uterine sarcoma is a rare entity often diagnosed at the time of surgery. Patients may present with pelvic pain, vaginal discharge, or hemodynamic shock. Clinically, the diagnosis may be suspected if there is a large vaginal mass and difficulty in palpating the cervix. Four surgical procedures have been described to manage non-puerperal uterine inversion, two by the abdominal route and two by the vaginal route. The Haultain procedure performed abdominally is preferred for uterine sarcomas as it facilitates reversion of the uterus vaginally or excision of the pedicle and removal of the prolapsed tumor vaginally. We describe a patient with this condition managed by the Haultain procedure.

Uterine Sarcomas: Histology and Its Implications on Therapy

2012 ◽  
pp. 356-361 ◽  
Author(s):  
Martee L. Hensley
Keyword(s):  
High Risk ◽  
Metastatic Disease ◽  
Objective Response ◽  
The United States ◽  
Good Prognosis ◽  
Uterine Sarcoma ◽  
Low Grade ◽  
High Grade ◽  
Limited Disease ◽  
Uterine Sarcomas

Overview: Uterine sarcomas are rare cancers, they comprise only 5% of all uterine malignancies. There are about 2,000 cases of uterine sarcoma diagnosed annually in the United States. Uterine sarcomas may be categorized as either favorable-risk, low-grade malignancies with a relatively good prognosis or as poor-risk, high-grade cancers that carry a high risk for tumor recurrence and disease progression. Expert histologic review is critical for appropriate diagnosis and management. Uterine sarcoma histologies considered to carry a more favorable prognosis include low-grade endometrial stromal sarcomas and adenosarcomas. The high-grade sarcomas include high-grade leiomyosarcomas, high-grade undifferentiated endometrial sarcomas, and adenosarcomas with sarcomatous overgrowth. The favorable histology, low-grade uterine sarcomas may be cured with surgical resection of uterus-limited disease. These tumors are often hormone-sensitive, and treatment with hormonal therapies may be efficacious for patients with advanced, unresectable disease. High-grade uterine leiomyosarcomas and undifferentiated endometrial sarcomas carry a high risk for recurrence, even after complete resection of uterus-limited disease. No adjuvant intervention has been shown to improve survival outcomes. Advanced, metastatic disease is generally treated with systemic cytotoxic therapies, which may result in objective response but is not curative. Selected patients with isolated metastatic disease and a long disease-free interval may benefit from metastatectomy.

Sign in / Sign up

Export Citation Format

Share Document